Part II of a Trilogy on Alignment in Digital Health
In my December reflection: A Year End Reflection on Innovation, I argued that most delays in pharma and diagnostics are not scientific, but structural. Driven by misalignment across decision lenses and ecosystem forces.
This second post is a deliberate continuation.
If misalignment is the hidden tax on innovation, then alignment cannot remain accidental.
Across digital health, alignment is often assumed to emerge once the science is strong enough or the technology mature enough. Experience shows the opposite. Alignment only appears when it is designed.
Digital pathology is one visible example of this dynamic: technically mature, clinically promising, yet still dependent on alignment across evidence, operations, regulation, and value. The same pattern is now repeating across AI enabled digital health more broadly.
In practice, alignment rests on six structural dimensions that must move together:
- Purpose: a shared understanding of the patient outcome being optimized
- Evidence: clarity on what fit for purpose data actually means across stakeholders
- Technology: platforms and AI designed as interoperable systems, not isolated components or closed integrated systems.
- Operations: clinical and laboratory workflows that can absorb innovation safely
- Regulation: early, transparent engagement with regulatory expectations
- Value: proof that innovation delivers clinical and economic impact
These are not sequential steps.
They are load bearing elements.
When one is weak, the system compensates elsewhere: with delays, rework, pilot fatigue, or stalled adoption. Speed is then forced where alignment is missing.
This is where leadership matters.
Alignment is not a coordination exercise delegated downstream. It is a leadership discipline requiring intent, structure, and sustained ownership across innovators, healthcare providers, payers, regulators, and pharma teams.
Organizations that master this do not move faster by chance.
They move faster because the system is designed to hold.
In the final post of this trilogy, I will explore what happens when alignment holds, when innovators and regulators move in concert, and execution finally follows insight.